06 Mar, 2024 Indefinite Contradiction or Inartful Claim Narrowing? By Chantelle Ankerman Earlier today the Federal Circuit in Maxell v. Amperex, No. 23-1194, vacated a District Court’s indefiniteness determination after...
21 Feb, 2024 “Inelegant” Language Does Not an Indefinite Claim Term Make By Chantelle Ankerman To follow up on my February 6, 2024 post, Federal Circuit Judges Prost, Taranto, and Chen heard oral argument on February 9, 2024 in...
06 Feb, 2024 Is a Claim Term’s Whole Greater Than the Sum of Its Parts? By Chantelle Ankerman Claim terms are usually given their ordinary meaning in light of the intrinsic evidence, but what if the ordinary meaning of two claim...
15 Dec, 2023 The Inflation Reduction Act’s First Potential Impact on Biosimilars By Ted Mathias Ross Blau Chantelle Ankerman On October 31, 2023, FDA approved Amgen’s Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Janssen’s Stelara...